Skip to content
Visit us at ASCO22 | June 3-7 | Booth #16113
Get expert insights on spatial biology & local attractions
Flagship Biosciences
  • About
    • Process
    • Technology
    • Company
    • Our Vision
    • Careers
  • Pharma
    • Image Analysis
    • IHC Assays / IF Assays / ISH Assays
      • Assay Solutions Listing
    • Multiplex Assays
    • Data Analysis and Reporting
    • Consultation with Scientific Experts
    • Regulatory Strategy and Support
  • CDx Development
  • Clinical Diagnostics
    • Clinical Data
    • Approved Partner Program
    • Scientific Advisory Board
  • Resources
    • News
    • Blog
    • Events
    • Posters & Publications
    • Collateral
  • Contact Us

POSTERS & PUBLICATIONS

Characterizing the Heterogeneity of CD8 Inflammation in Biopsied Tumor Tissues Using Novel Image Analysis Techniques (Poster No. 3137 #AACR2021 in partnership with Scholar Rock)

Key takeaways An image analysis-based algorithm was used to assess CD8 expression in numerous tumor nests in non-small cell lung cancer, bladder, and melanoma tumor

Read More »
April 8, 2021

A Novel Image Analysis Assay for Determining Programmed Death-Ligand (PD-L1 [22C3]) in Non-small Cell Lung Cancer that Accounts for Tissue and Alveolar Macrophages (Poster No. 435 #AACR2021)

Background The Dako PD-L1 (22C3) antibody is used to measure tumor PD-L1 levels in non-small cell lung cancer (NSCLC), serving as a companion diagnostic to

Read More »
April 8, 2021

Impact of adding Viagenpumatucel-L (HS-110) to Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Patients with Low Levels of Tumor Infiltrating Lymphocytes

Summary View a scientific, collaborative success with our client, Heat Biologics, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 medical oncology

Read More »
September 28, 2020

Image Analysis-Based Identification and Quantification of Macrophages in PD-L1 (22C3) Stained NSCLC Tissue Sections Without Additional Macrophage-Specific Staining

ABSTRACT PD-L1 positivity in tumor-associated macrophages has been related to a favorable response to anti-PD-1 and PD-L1 targeted therapies. This concept has driven interest in

Read More »
July 3, 2020

Protein Tyrosine Kinase 7 (PTK7) Biomarker Analysis in Patients treated with PF-06647020, a PTK7 Antibody-Drug Conjugate (ADC), in a Phase I Dose Expansion Study

BACKGROUND F-06647020, an ADC comprising a humanized monoclonal antibody against PTK7, a cleavable valine-citrulline linker, and an auristatin payload, is being investigated in an ongoing

Read More »
December 17, 2019

Comprehensive Image Analysis Of Immunostained NSCLC Tissues Provides Necessary Context For Immune Oncology Biomarker Profiling

Key Takeaways Manual pathology assessment is challenging and variable, limiting the data interpretation required for meaningful spatial biology analysis Unlike manual assessment, artificial intelligence and

Read More »
November 11, 2019
⟨ Page1 Page2 Page3 Page4 Page5 ⟩

Sign up to receive
industry and company
news, including
The Cut Point,
Flagship’s quarterly
e-newsletter.





Recent Posts

  • Recognizing women leaders in biotechnology
  • Flagship Spotlight: Jordyn Vincelet – Sales Coordinator at Flagship Biosciences
  • Tissue Based Companion Diagnostics in a Regulated Space
  • Flagship Spotlight: Roberto Gianani, MD
  • Flagship Spotlight: Adam Beharry

Resources

  • News
  • Blog
  • Events
  • Posters & Publications
  • Collateral

READY TO TAKE THE NEXT STEP?

Start Your Consultation Today

Our Services

Pharma

Cell-based image analysis, assays, and partnership to advance clinical trials and regulatory acceptance.

Learn More

Clinical Diagnostics

Dependable clinical diagnostic testing to connect patients to individualized, immuno-oncology therapies.

Learn More

Related Resources

Blog

Posters & Publications

News

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.
Sr. Pharmaceutical Research Director
Sr. Pharmaceutical Research Director
We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.
Biopharma Director
Biopharma Director
During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.
Biotech Pharmaceutical Operations Director
Biotech Pharmaceutical Operations Director
We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.
Laboratory Software Solutions Provider COO
Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.
Sr. Pharmaceutical Research Director
Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.
Global Oncology Research Database Provider CEO
The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.
CIO Review, Pharma and Life Sciences

About Flagship Biosciences

We are a multi-disciplinary team of pathologists, biologists, analysts, software engineers, and technicians who are committed to creating successful approaches which match patients with life-saving drugs.
Learn More >

CAP and CLIA logos

Quick Links

  • Pharma
  • CDx Development
  • Clinical Diagnostics
  • Posters & Publications
  • Events
  • Careers
  • Contact Us
Menu
  • Pharma
  • CDx Development
  • Clinical Diagnostics
  • Posters & Publications
  • Events
  • Careers
  • Contact Us

Connect With Us

Linkedin Facebook Twitter Envelope

11800 Ridge Parkway, Suite 450
Broomfield, CO 80021
303.325.5894

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.



 
 


  • Copyright 2022 Flagship Biosciences Inc.
  • Privacy Policy
  • 11800 Ridge Parkway, Suite 450, Broomfield, CO 80021
Search for:
Close Menu
Manage Cookie Consent
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of all cookies.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
Preferences
{title} {title} {title}



×



×



×

Start Your Consultation Today